ClinicalTrials.gg
CompletedNCT05352516Updated Sep 20, 2024

A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

A Phase 3 interventional study of HLX14 and Prolia® in Postmenopausal, sponsored by Shanghai Henlius Biotech. Completed at 38 sites in China. Open to female participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-09-20.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
514
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
Female
01

Study summary

This is a randomized, double-blind, international multicentre, parallel-controlled phase III clinical study.

The study plans to enroll 478 postmenopausal women with osteoporosis at high risk of fracture, whom will be randomized at 1:1 to either the experiment group (HLX14) or the control group (Prolia®) based on stratification factors (BMI (\< 25, 25-30, > 30) and geographic region (Asian or non-Asian)).

The study includes screening period (28 days), treatment period (total 546 days, contain treatment period 1: D1-D364, treatment period 2: D365-D546), and an end-of-study visit (D547).

Read the detailed description
  • Screening period: From Day -28 to -1, all female with postmenopausal osteoporosis subjects at high risk of fracture sign the informed consent form (ICF) and undergo relevant tests. Those who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned into either experiment group (HLX14) or control group (Prolia®) at 1:1 and then enter the treatment period. Vitamin D and calcium supplementation is allowed during the screening period.
  • Treatment period: Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 or Prolia® (once every 6 months (Q6M)).

Treatment period 1: D1-D364, subjects will receive subcutaneous injection of HLX14 or Prolia® 60mg on D1 and D183.

Treatment period 2: D365-D546, on D365, subjects in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to HLX14 and receive a single dose of HLX14. Subjects in the HLX14 arm will be continue with a third dose of HLX14.

  • During the treatment period, subjects should taking at least 1000 mg of calcium daily and at least 400 IU of vitamin D daily until the end of study. (Dose will be adjusted by the investigator based on serum calcium)
  • End-of-study visit: The end-of-study visit will be conducted on D547 of the study or premature withdrawal. Only serious adverse events related to the investigational product will be recorded thereafter.
02

Conditions studied

  • Postmenopausal
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ambulatory women with osteoporosis aged 60-90 years (both inclusive);
  2. Postmenopausal, defined as > 2 years of menopause, i.e., > 2 years of spontaneous amenorrhea or > 2 years after bilateral oophorectomy;
  3. Bone mineral density (BMD) T-score between -2.5 and -4.0 at the lumbar spine or total hip, i.e., -4.0 \< T-score ≤ -2.5, as assessed by the central imaging vendor at the time of screening, based on dual-energy x-ray absorptiometry (DXA) scans;
  4. At least 2 vertebrae in the L1-L4 region of lumbar spine and at least one hip are evaluable by DXA, assessed by the central imaging

Exclusion criteria

Exclusion criteria:

  1. Diseases that may affect bone metabolism;
  2. Thyroid disorders;
  3. With serious primary diseases in the cardiovascular, cerebrovascular, or hematopoietic system;
  4. Subjects with rheumatoid arthritis or ankylosing spondylitis;
  5. Malabsorption syndrome or various gastrointestinal disorders associated with malabsorption;
  6. Severe renal impairment due to renal disease with a \< 30 mL/min;
  7. Hepatic diseases;
  8. With serious primary diseases in the cardiovascular, cerebrovascular, or hematopoietic system judged by investigator;
  9. Positive for (HIV) antibody;
  10. Vitamin D deficiency;
  11. Abnormal serum calcium;
  12. Oral and dental diseases;
  13. Active or uncontrolled infection requiring systemic therapy within 2 weeks prior to first dose;
  14. Type 1 diabetic patients, or type 2 diabetic patients who have poor blood glucose control or are treated with insulin, glucagon-like peptide-1 (GLP-1), thiazolidinediones, SGLT2 inhibitors, etc;
  15. Participating in clinical trials of other medical devices or drugs or reaching less than 30 days or 5 half-lives after the last visit in the clinical trials of other medical devices or drugs (non-bone metabolism related drugs) (whichever is longer, calculated from the date of ICF signing). Bone metabolism related drugs should comply with the corresponding prohibition time limit, and anti-osteoporosis drugs should be excluded. Those who have failed in the screening period of other clinical trials but have not yet been treated with drugs/clinical devices can be included in this study;
  16. Having received Denosumab and its biosimilars, or Romosozumab and its biosimilars, cathepsin K inhibitor therapy prior to randomization;
  17. Having received the following osteoporosis treatments, or medications that affect bone metabolism or any herbal medications:
  1. Use of bisphosphonates(oral or intravenous) ,fluoride and strontium prior to randomization.
  1. Use of parathyroid hormone (PTH) or PTH analogues, such as teriparatide, within 12 months prior to randomization.
  1. Use of systemic hormone replacement therapy (HRT), selective estrogen receptor modulators, tibolone, anabolic hormones, testosterone, androgens, gonadotropin releasing hormone agonists, adrenocorticotropic hormone, within 12 months prior to randomization.
  1. Use of calcitonin, calcitriol, alfacalcidol and vitamin D analogues within 12 months prior to randomization: 5) Use of any of the following within 3 months prior to randomization: heparin, warfarin, anticonvulsants (except benzodiazepines), systemic use of ketoconazole, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, and oral or parenteral (≥ 5 mg/day prednisone daily or equivalent for > 10 days).
  1. Use of any herbal medications within 2 weeks (If the herbal medications contain the above components that affect bone metabolism, should follow the corresponding elution period of bone metabolism components);
  1. Subjects with a history or presence of hip fracture or .prevalent vertebral (any severe or more than 2 moderate prevalent vertebral fractures);
  1. Subjects in active healing fracture in the opinion of the investigator;
  1. Subjects at very high risk of fracture who must be treated immediately with an active drug in the opinion of the investigator;
  1. Known allergic to the drugs listed in the study protocol, including a history of allergy to denosumab, any recombinant protein drugs, or any ingredients used in HLX14 or Prolia®;
  1. With a history and presence of smoking, except for the following suituation:
  1. non-smokers (A history of never smoking > 5 cigarettes/day and not smoking at all for at least the last 2 years prior to screening process)
  2. light smokers (with smoking habit \<5 cigarettes/day, smoking period \<10 years. Light smokers should have not smoked more than 1 cigarette in the week before starting the medical screening process)
  1. With a history of drug or alcohol abuse, and with evidence of alcohol or drug abuse within 12 months;
  1. Various physical or psychiatric disorders or laboratory abnormalities which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of study results. Or the subjects presenting other factors not suitable for participation in the opinion of the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
514 participants (actual)

Study arms

  • Experimental
    Treatment group

    Biological: HLX14

  • Active comparator
    Control group

    Biological: Prolia®

Interventions

  • BiologicalHLX14

    Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 (once every 6 months (Q6M)). Treatment period 1: D1-D364, subjects will receive subcutaneous injection of HLX14 60mg on D1 and D183. Treatment period 2: D365-D546, on D365, subjects will be continue with a third dose of HLX14.

  • BiologicalProlia®

    Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 or Prolia® (once every 6 months (Q6M)). Treatment period 1: D1-D364, subjects will receive subcutaneous injection of Prolia® 60mg on D1 and D183. Treatment period 2: D365-D546, on D365, subjects in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to HLX14 and receive a single dose of HLX14.

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint

    Percent change from baseline in BMD at the lumbar spine to Week 52 (D365) (assessed by the central imaging). Note: The percent change in BMD is calculated as: (Test value - Baseline value) / (Baseline Value) × 100%

    Time frame: 52 Weeks

  2. Primary pharmacodynamic endpoint

    Area under the effect-time curve for percent change from baseline of serum type I collagen C-telopeptide (s-CTX) from 0 to Week 26 (D183) (AUEC0-26W)

    Time frame: 26 Weeks

Secondary outcomes

  1. Secondary efficacy endpoint

    1. Percent change from baseline in BMD at the lumbar spine to Week 26 (D183), Week 52 (D365),Week78 (D547) (assessed by investigator). 2. Fracture rate from baseline to Week 52 (D365), Week 78 (D547). 3. Percent change in BMD at lumbar spine from baseline to Week 26 (D183), Week 78 (D547) (assessed by the central imaging). 4. Percent change in BMD at total hip from baseline to Week 26 (D183), Week 52 (D365) and Week 78 (D547) (assessed by the central imaging and investigator). 5. Percent change in BMD at the femoral neck from baseline to Week 26 (D183), Week 52 (D365) and Week 78 (D547) (assessed by the central imaging and investigator). Note: Fracture rate=(number of patients with new fractures/total number of patients)\*100% The percent change in BMD is calculated as (test value - baseline value) ÷ (baseline value) × 100%

    Time frame: 78 Weeks

  2. Secondary pharmacodynamic endpoint

    1. Relative percent change in serum type I collagen C-telopeptide (s-CTX) from baseline to D15, D29, D57, D92, D106, D134, D162, D183 (within 7 days prior to the second dose), D274, D365 (within 7 days prior to the third dose), and D547 (at the end-of-study visit). 2. Relative percent changes in serum procollagen type I N propeptide (s-P1NP) from baseline to D15, D29, D57, D92, D106, D134, D162, D183 (within 7 days prior to the second dose), D274, D365 (within 7 days prior to the third dose) and D547 (at the end-of-study visit). The relative percent change is calculated as: (Test value at timepoints evaluated - Baseline value) / (Baseline value) × 100%

    Time frame: 78 Weeks

07

Study locations

38 sites
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Ha'erbin, Heilongjiang, China
  • Inner Mongolia Baogang hospital
    Baotou, Inner Mongolia, China
  • Huai'an First People's Hospital
    Huai'an, Jiangsu, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
  • Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
  • Ruian People's Hospital
    Rui'an, Jiangxi, China
  • People's Hospital of Ningxia Hui Autonomous Region
    Yinchuan, Ningxia, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
  • Beijing BOAI Hospital
    Beijing, China
  • Beijing Hospital
    Beijing, China
  • Beijing Jishuitan Hospital
    Beijing, China
  • BeiJing PINGGU Hospital
    BeiJing, China
  • The Third Xiangya Hospital of Central South University
    Changsha, China
  • Changzhou NO.2 People's Hospital
    Changzhou, China
  • West China Hospital of Sichuan University
    Chengdu, China
  • Chongqing University three Gorges Hospital
    Chongqing, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, China
  • Department of Geriatrics, Guangzhou First People's Hospital
    Guangzhou, China
  • Guangzhou First People's Hospital
    Guangzhou, China
  • The First Affiliated Hospital of USTC Anhui Provincial Hospital
    Hefei, China
  • Qilu Hospital of Shandong University
    Jinan, China
  • Shandong Provincial Hospital
    Jinan, China
  • Affiliated Hospital of Jining Medical University
    Jining, China
  • The Third People's Hospital of Yunnan Province
    Kunming, China
  • Henan Luoyang Orthopedic Hospital
    Luoyang, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, China
  • Jiangxi Provincial People's Hospital
    Nanchang, China
  • Nanchang Hongdu Hospital of traditional Chinese Medicine
    Nanchang, China
  • Nanchang Third Hospital
    Nanchang, China
  • Pingxiang Peoples's Hospital
    Pingxiang, China
  • Suining Central Hospital
    Suining, China
  • First Hospital of Shanxi Medical University
    Taiyuan, China
  • Second hospital of Shanxi Medical University
    Taiyuan, China
  • Tianjin First Central Hospital
    Tianjin, China
  • Weifang People's Hospital
    Weifang, China
  • Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology
    Wuhan, China
  • Honghui Hospital,Xi'an Jiaotong University
    Xi'an, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Dec 2023, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2022
First posted
Apr 28, 2022
StartActual
Jun 17, 2022
Primary completionActual
Dec 17, 2023
CompletionActual
Jul 3, 2024
Last update
Sep 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05352516
Responsible party
Sponsor
First posted
Apr 28, 2022
Start date
Jun 17, 2022
Primary completion
Dec 17, 2023
Completion
Jul 3, 2024
Last update
Sep 20, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion